Process impurity revelation rocks Reata

11 May 2023
reata_large

Shares in Texan pharma company Reata Pharmaceuticals (Nasdaq: RETA) closed 15% lower on Wednesday.

The company had earlier revealed a setback with Skyclarys (omavaloxolone), which in March became the first drug to win US Food and Drug Administration (FDA) approval to specifically treat the rare neuromuscular disease Friedreich's ataxia.

In presenting its first-quarter financial results, Reata gave an update on its progress with bringing the Nrf2 activator to market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology